Aptiganel

Aptiganel
Clinical data
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name 1-(3-ethylphenyl)-1-methyl-2-naphthalen-1-yl-guanidine;
CAS Number	137159-92-3 ;
PubChem CID	60840;
ChemSpider	54827 ;
UNII	46475LV84I;
ChEMBL	ChEMBL92484 ;
CompTox Dashboard (EPA)	DTXSID4048432 ;
Chemical and physical data
Formula	C20H21N3
Molar mass	303.409 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1=CC(=CC=C1)N(C)C(=NC2=CC=CC3=CC=CC=C32)N;
	InChI InChI=1S/C20H21N3/c1-3-15-8-6-11-17(14-15)23(2)20(21)22-19-13-7-10-16-9-4-5-12-18(16)19/h4-14H,3H2,1-2H3,(H2,21,22) ; Key:BFNCJMURTMZBTE-UHFFFAOYSA-N ;
	(what is this?) (verify)

Aptiganel (Cerestat; CNS-1102) is an unsuccessful drug candidate which acts as a noncompetitive NMDA antagonist, and that was under development by Cambridge Neuroscience, Inc as a treatment for stroke.^[1] It has neuroprotective effects and was researched for potential use in the treatment of stroke,^[2] but despite positive results in animal studies,^[3] human trials showed limited efficacy,^[4] as well as undesirable side effects such as sedation and hallucinations,^[5]^[6] and clinical development was ultimately not continued.^[7]